http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022221443-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ce22998f19d91fa0865393a7c03e22a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2033-4975 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6812 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-4972 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-082 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2020-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf53aacbf3f31240194f3e817f82f4e3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c109629165e64c19d493d7673f9b7f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c89ae44bb4b4802045008b397ea93aee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbe395ff824475741abe7106494dd937 |
| publicationDate | 2022-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022221443-A1 |
| titleOfInvention | Biomarker detection for cancer diagnosis and prognosis |
| abstract | The invention relates to a method for diagnosing a subject suffering from cancer, or a pre-disposition thereto. The method comprises detecting, in a bodily sample from a test subject, the concentration of a signature compound resulting from the metabolism of at least one sugar, and/or at least one amino acid or a precursor thereof, and/or at least one polyol present in a composition previously administered to the subject. The sugar is present in the composition at a concentration of more than 20,000 mg/100 ml, the amino acid or a precursor thereof is present in the composition at a concentration of at least 500 mg/ml, and the polyol is present in the composition at a concentration of more than 25,000 mg/100 ml. The method further comprises comparing this concentration with a reference for the concentration of the signature compound in an individual who does not suffer from cancer. In particular, an increase or decrease in the concentration of the signature compound compared to the reference, suggests that the subject is suffering from cancer, or has a pre-disposition thereto, or provides a negative prognosis of the subject's condition. |
| priorityDate | 2019-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 299.